RxDoctor Payments Data

Gaurav Mathur, MD

Cardiovascular Disease · Weeki Wachee, FLNPI 1043524176

Payments from drug & device makers

$3,281in general payments, 2019–2025

Across 112 payments — averaging $29.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Medtronic$528
  • Boehringer Ingelheim$333
  • Amgen$231
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$194
  • Pfizer$151
  • plus $758 from 17 others

What the payments were for

  • Food & beverage$3,281100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,281 in reported general payments places this provider in the 45th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$704,086
Medicare patients
974
Services billed
11,803

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban329$431,685
XareltoRivaroxaban66$81,608
EntrestoSacubitril/Valsartan35$36,521
JardianceEmpagliflozin31$35,037
Repatha SureclickEvolocumab31$32,968
FarxigaDapagliflozin Propanediol21$28,977
OzempicSemaglutide25$27,846
BrilintaTicagrelor17$20,266
Ranolazine ErRanolazine127$18,993
Praluent PenAlirocumab16$16,874
Repatha SyringeEvolocumab16$15,791
Metoprolol Succinate659$10,351
EdarbyclorAzilsartan Med/Chlorthalidone21$8,505
ClopidogrelClopidogrel Bisulfate383$5,338
Bisoprolol Fumarate150$5,020

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$151$431,685329 claims
Johnson & JohnsonXarelto$141$81,60866 claims
AstraZenecaFarxiga, Brilinta$58$49,24338 claims
NovartisEntresto$73$36,52135 claims
Boehringer IngelheimJardiance$333$35,03731 claims
Novo NordiskOzempic$56$27,84625 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Weeki Wachee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →